Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
NEW YORK, March 08, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Ophthotech Corporation (“Ophthotech”) (NASDAQ:OPHT) between May 11, 2015 and December 12, 2016. You are hereby notified that Levi & Korsinsky has commenced the class action Micholle v. Ophthotech Corporation, et al. (Case No. 1:17-cv-00210) in the USDC for the Southern District of New York. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the Class Period, Ophthotech made overtly positive representations about the effectiveness and potential of its treatment Fovista when used in combination with Lucentis, a commercially available anti-vascular endothelial growth factor agent, despite awareness that the phase 3 clinical trial of Fovista would fail to achieve its primary endpoint of change in best corrected visual acuity from baseline at 12 months over Lucentis alone. The complaint further alleges that these statements caused Ophthotech stock to trade at artificially inflated prices.
On December 12, 2016, Ophthotech announced that the trial had failed to achieve its primary endpoint, and that Fovista and Lucentis demonstrated a non-statistically significant improvement over patients only receiving Lucentis. Following this news, shares of Ophthotech fell approximately 86% to close at $5.29.
Take Action: if you suffered a loss in Ophthotech you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
